Chat with us
Research Assistance
Online
  • Please enter your first name.

Latin America Meningococcal Vaccines Market Size & Outlook

The meningococcal vaccines market in Latin America is expected to reach a projected revenue of US$ 176.2 million by 2033. A compound annual growth rate of 5.9% is expected of Latin America meningococcal vaccines market from 2026 to 2033.
Revenue, 2025 (US$M)
$107.0
Estimate, 2026 (US$M)
$118.1
Forecast, 2033 (US$M)
$176.2
CAGR, 2026 - 2033
5.9%
Latin America Meningococcal Vaccines Market, 2021-2033 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Latin America meningococcal vaccines market highlights

  • The Latin America meningococcal vaccines market generated a revenue of USD 107.0 million in 2025.
  • The market is expected to grow at a CAGR of 5.9% from 2026 to 2033.
  • In terms of segment, menveo was the largest revenue generating brand in 2025.
  • Nimenrix is the most lucrative brand segment registering the fastest growth during the forecast period.
  • Country-wise, Argentina is expected to register the highest CAGR from 2026 to 2033.


Latin America data book summary

Market revenue in 2025USD 107.0 million
Market revenue in 2033USD 176.2 million
Growth rate5.9% (CAGR from 2026 to 2033)
Largest segmentMenveo
Fastest growing segmentNimenrix
Historical data covered2021 - 2024
Base year for estimation2025
Forecast period covered2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationMenactra, Menveo, Nimenrix, Trumenba, Bexsero
Key market players worldwidePfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology


Other key industry trends

  • In terms of revenue, Latin America region accounted for 2.6% of the global meningococcal vaccines market in 2025.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2033.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 1,007.4 million by 2033.

In Latin America region, Brazil, Mexico, Argentina are major market for meningococcal vaccines. According to an article published in the International Journal of Infectious Disease, in 2019, Brazil, Chile, and Argentina reported the highest number of IMD cases, whereas Mexico recorded lowest disease incidence, due to underreporting of cases.

Increase in the incidence of meningitis serogroup A, B, C, Y, & W leads to rise in mortality rates, which is expected to fuel market growth. Due to low awareness level about meningococcal disease among people and underreported cases of IMD underestimate the real burden of the disease in the region.

However, improvement in meningococcal disease diagnosis, monitoring, and registration is anticipated to boost market growth during the forecast period. Presence of favorable government initiatives and research collaborations are anticipated to contribute to market growth.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Three ways to get this data

Subscribe to the databook, customize it, or ask a question.

Horizon Databook

Unlock every chart on this page and get dashboard access

  • Statistics1.2M+ across all markets
  • Databooks30K+ global, 120K+ country
  • Companies200K+ profiles
  • ExportPDF, Dashboard, XLS & PNG, licensed to cite

Ask Prism AI

A cited answer in seconds

  • Corpus30,000 studies, 1.2M points
  • ScopeAll markets, not just this
  • CitationTraced to report & table
  • HonestySays "not covered" if so
  • SpeedSeconds, not days
ISO 9001 & 27001 certifiedESOMAR memberNot sure which fits? Call +1-415-854-0727

Meningococcal Vaccines Market Companies

NameProfile# EmployeesHQWebsite
Pfizer IncView profile 88,00066 Hudson Boulevard East, New York, NY, United States, 10001-2192www.pfizer.com
Sanofi SAView profile 87,99446, avenue de la Grande Armée, Paris, France, 75017www.sanofi.com
Merck & Co IncView profile 72,000126 East Lincoln Avenue, Rahway, NJ, United States, 07065www.merck.com
GSK PLCView profile 70,200980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GSwww.gsk.com
Serum Institute of India Pvt. Ltd.View profile 1001-5000Pune, Maharashtra, India, Asiawww.seruminstitute.com/
Walvax BiotechnologyView profile 11-50Kunming, Yunnan, China, Asiawww.walvax.com

Latin America Meningococcal Vaccines Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Meningococcal Vaccines Market Outlook will help companies and investors design strategic landscapes.


Menveo was the largest segment with a revenue share of 32.99% in 2025.

Horizon Databook has segmented the Latin America meningococcal vaccines market based on menactra, menveo, nimenrix, trumenba, bexsero covering the revenue growth of each sub-segment from 2021 to 2033.




In Latin America region, Brazil, Mexico, Argentina are major market for meningococcal vaccines. According to an article published in the International Journal of Infectious Disease, in 2019, Brazil, Chile, and Argentina reported the highest number of IMD cases, whereas Mexico recorded lowest disease incidence, due to underreporting of cases.

Increase in the incidence of meningitis serogroup A, B, C, Y, & W leads to rise in mortality rates, which is expected to fuel market growth. Due to low awareness level about meningococcal disease among people and underreported cases of IMD underestimate the real burden of the disease in the region.

However, improvement in meningococcal disease diagnosis, monitoring, and registration is anticipated to boost market growth during the forecast period. Presence of favorable government initiatives and research collaborations are anticipated to contribute to market growth.

  • Latin America Meningococcal Vaccines Market Brand Outlook (Revenue, USD Million , 2021-2033)
    • Menactra
    • Menveo
    • Nimenrix
    • Trumenba
    • Bexsero
    • Others
  • Latin America Meningococcal Vaccines Market Serotype Outlook (Revenue, USD Million , 2021-2033)
    • A
    • B
    • C
    • W-135
    • Y
  • Latin America Meningococcal Vaccines Market Age Group Outlook (Revenue, USD Million , 2021-2033)
    • Infants (0 to 2 years)
    • Children and Adults (2 years and above)
  • Latin America Meningococcal Vaccines Market Sales Channel Outlook (Revenue, USD Million , 2021-2033)
    • Private
    • Public
  • Latin America Meningococcal Vaccines Market Type Outlook (Revenue, USD Million , 2021-2033)
    • Bivalent
    • Quadrivalent
    • Others

Reasons to subscribe to Meningococcal Vaccines Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Meningococcal Vaccines Market Outlook databook

  • Our clientele includes a mix of Meningococcal Vaccines Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America Meningococcal Vaccines Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Latin America Meningococcal Vaccines Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Latin America Meningococcal Vaccines Market, 2021-2033 (US$M)

No Access Stack Chart

Latin America Brand - Meningococcal Vaccines Market Statistics, 2025 - 2033 (US$M)

No Access Pie Chart

Latin America meningococcal vaccines market statistics, by country, 2021-2033 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more